Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Offin

Showing results (1-10 of 88) with videos related to

Pageof 9
Sort By:
The Lancet. Oncology|March 31, 2022
ARCS-M: forging progress from this negative trial in malignant pleural mesotheliomaMarjorie G Zauderer, Michael Offin
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Tumor-Agnostic Drug DevelopmentMichael Offin, Dazhi Liu, Alexander Drilon
Journal of Cancer Metastasis and Treatment|June 19, 2024
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomasMichael Offin, Bailey Fitzgerald, Marjorie G Zauderer, et al.
The Western Journal of Emergency Medicine|April 3, 2015
Structured communication: teaching delivery of difficult news with simulated resuscitations in an emergency medicine clerkshipSangeeta Lamba, Roxanne Nagurka, Michael Offin, et al.
Journal of Thoracic Disease|January 12, 2019
Liquid biopsy guided precision therapy for lung cancersChongrui Xu, Michael Offin, Paul K Paik, et al.
Therapeutics and Clinical Risk Management|July 28, 2018
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumorsDazhi Liu, Michael Offin, Stephen Harnicar, et al.
JTO Clinical and Research Reports|February 20, 2026
ALK Inhibitor Response in Novel <i>ZFPM2::ALK</i> and <i>TRIM24::ALK</i> Fusion-Positive Lung Cancers: Case ReportCharles Hsu, Mohamed Yakoub, Michael Offin, et al.
The Oncologist|June 16, 2022
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical PracticeMichael Offin, Valerie W Rusch, Andreas Rimner, et al.
Journal of Oncology|April 11, 2017
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNAMichael Offin, Jacob J Chabon, Pedram Razavi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2021
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trialsNavin K Chintala, David Restle, Hue Quach, et al.
Pageof 9

Showing results (1-10 of 88) with videos related to

Sort By:
Pageof 9
The Lancet. Oncology|March 31, 2022
ARCS-M: forging progress from this negative trial in malignant pleural mesotheliomaMarjorie G Zauderer, Michael Offin
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|September 21, 2018
Tumor-Agnostic Drug DevelopmentMichael Offin, Dazhi Liu, Alexander Drilon
Journal of Cancer Metastasis and Treatment|June 19, 2024
The past, present, and future of targeted therapeutic approaches in patients with diffuse pleural mesotheliomasMichael Offin, Bailey Fitzgerald, Marjorie G Zauderer, et al.
The Western Journal of Emergency Medicine|April 3, 2015
Structured communication: teaching delivery of difficult news with simulated resuscitations in an emergency medicine clerkshipSangeeta Lamba, Roxanne Nagurka, Michael Offin, et al.
Journal of Thoracic Disease|January 12, 2019
Liquid biopsy guided precision therapy for lung cancersChongrui Xu, Michael Offin, Paul K Paik, et al.
Therapeutics and Clinical Risk Management|July 28, 2018
Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of <i>NTRK</i>, <i>ROS1</i>, and <i>ALK</i> fusion-positive solid tumorsDazhi Liu, Michael Offin, Stephen Harnicar, et al.
JTO Clinical and Research Reports|February 20, 2026
ALK Inhibitor Response in Novel <i>ZFPM2::ALK</i> and <i>TRIM24::ALK</i> Fusion-Positive Lung Cancers: Case ReportCharles Hsu, Mohamed Yakoub, Michael Offin, et al.
The Oncologist|June 16, 2022
Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical PracticeMichael Offin, Valerie W Rusch, Andreas Rimner, et al.
Journal of Oncology|April 11, 2017
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNAMichael Offin, Jacob J Chabon, Pedram Razavi, et al.
Lung Cancer (Amsterdam, Netherlands)|May 11, 2021
CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trialsNavin K Chintala, David Restle, Hue Quach, et al.
Pageof 9